Expression of bone morphogenetic protein 2 and its role in prognosis evaluation in gliomas / 中华神经医学杂志

ABSTRACT

Objective:To study the mRNA expressions of bone morphogenetic protein 2 ( BMP2) in different types of gliomas and the relation between BMP2 mRNA expression and survival time, and to explore the role of BMP2 mRNA expression in prognosis evaluation in gliomas. Methods:The clinical data of 692 patients with gliomas in China Glioma Genome Atlas (CGGA) database were collected. Differences of BMP2 mRNA expression were compared among glioma patients with different histophiologic types, and patients with different gender and different ages, patients at primary or recurrent status, and those with different WHO grading, isocitrate dehydrogenase 1 (IDH1) mutation, 1P19q heterozygous deletion status, and molecular typing. The difference in survival time between patients with high and low BMP2 mRNA expression levels were compared in different categories of gliomas. Results:(1) The BMP2 mRNA expressions were different in different histopathological types of gliomas ( F=9.392, P=0.000); BMP2 expression in the oligodendroglioma subtype was the highest, followed by astrocytoma subtype and glioblastoma. The BMP2 relative mRNA expressions in male and female patients were 9.78±0.65 and 11.26±0.86, respectively, without statistical difference ( P>0.05). The BMP2 relative mRNA expressions in patients <43 years old and patients≥43 years old were 12.51±0.81 and 8.37±0.65, respectively, with significant difference ( P<0.05). The BMP2 relative mRNA expressions were 10.09±0.62 and 10.90±0.93, respectively, without significant difference ( P>0.05). The BMP2 relative mRNA expressions were 13.98±1.12, 12.88±0.88 and 5.18±0.64 in WHO grading II, III, and IV gliomas patients, respectively, with significant differences ( F=30.912, P=0.000). The BMP2 relative mRNA expressions in patients with IDH1 wild-type and IDH1 mutant were 2.73±0.16 and 17.47±0.85, respectively, with significant difference ( P<0.05). The BMP2 relative mRNA expressions in patients with 1P/19Q non-absence and 1P/19Q absence were 7.02±0.36 and 25.28±1.66, respectively, with significant difference ( P<0.05). In patients with lower graded glioma and glioblastoma, the BMP2 mRNA expressions in these patients with IDH mutation were significantly higher than those in patients with IDH wild-type ( P<0.05). (2) In patients with primary glioma and patients with recurrent glioma, the survival time of these patients with high BMP2 mRNA expression (≥4.68) was significantly longer than that of patients with low expression (<4.68, χ2=62.975, P=0.000; χ2=12.810, P=0.000). Conclusion:The BMP2 mRNA expression can be used as an index to predict the malignant degrees of gliomas; patients with high expression have longer survival time than those with low expression.